Investors2022-01-14T09:14:24+00:00

Investor Information

Stock Chart

View Listing

Investor News

Dr Dingle Spence to speak at two conferences on psychedelics

October 13, 2021|

Dr. Spence, an oncologist, palliative care specialist, and health justice activist will speak at the EndWell Conference – “The End in Mind – Psychedelic Medicines & Ending Well” taking place virtually on Thursday, October 14, 2021. Dr. Spence is also a featured speaker at the “Fantastic Fungi Global Summit – The Transformational Power of Mushrooms” taking place virtually on Friday, Saturday, and Sunday October 15-17th 2021.

  • Pure Psyence | Pure Extract | Psyence

Pure Psyence: A Joint Venture Sealed between Psyence Group and Pure Extracts

September 28, 2021|

Our Joint Venture with Pure Extracts, "Pure Psyence", is an important milestone for Psyence Group. Pure Psyence will develop nature-derived psilocybin extracts, and advanced psilocybin formulations, for the long-term treatment of psychological trauma and its mental health consequences. The JV's combined expertise in formulation development of psychoactive compounds will enable Pure Psyence to produce stable and effective psilocybin medicinal products and work towards making psilocybin more accessible.

Psyence Group announces the commencement of online sales and distribution of “GOODMIND™” products

August 18, 2021|

We are excited that as of today our functional mushroom nutraceutical product, GOODMIND™ is available online. The GOODMIND™ formulas harness the power of adaptogens, these are non-toxic, non-psychoactive fungi, used for centuries in traditional medicine for their stress-relieving benefits. GOODMIND™ is designed to nourish the mind and elevate everyday life by enhancing mental capacity and the body’s ability to adapt to stress.

  • Clerkenwell | Psyence | Psilocybin

Psyence Group and UK Psychedelic CRO Partners to Conduct UK Palliative Care Clinical Trial

July 7, 2021|

Psyence has signed a partnership agreement with Clerkenwell Health, a leading psychedelic Contract Research Organisation (CRO) based in the United Kingdom to develop market leading clinical trials in the field of palliative care. Clerkenwell will be responsible for jointly designing and delivering the UK clinical trial. Palliative care is the treatment and alleviation of suffering for those facing a serious acute or persistent medical issue, whether the prognosis is deemed terminal or chronic and ongoing.

  • Neil Maresky

Psyence Group Announces Appointment of New Chief Executive Officer

June 28, 2021|

Today Dr. Neil Maresky joins Psyence as Chief Executive Officer. Dr. Maresky brings more than 20 years of biopharmaceutical expertise to our team; he will oversee strategy and operations of Psyence, and will be based in Canada. Dr. Maresky has been instrumental in the launch, commercialization, and uptake of many ground breaking innovations, which have positively impacted the health of millions of patients across Canada.

Investor News

  • Real Psilocybin | Psychedelic Mushrooms

Psyence completes its first official, validated harvest of psychedelic mushrooms

Psyence Group is one step closer to achieving British Standards Institute (BSI) certification , having completed its first official validated harvest of psychedelic mushrooms (psilocybe cubensis) at its federally-licensed facility In Lesotho, Southern Africa. The state-of-the-art facility has been built to GMP standards, is FDA registered and has been operational since January 2021.

  • Pure Psyence | Pure Extract | Psyence

Pure Psyence: A Joint Venture Sealed between Psyence Group and Pure Extracts

Our Joint Venture with Pure Extracts, "Pure Psyence", is an important milestone for Psyence Group. Pure Psyence will develop nature-derived psilocybin extracts, and advanced psilocybin formulations, for the long-term treatment of psychological trauma and its mental health consequences. The JV's combined expertise in formulation development of psychoactive compounds will enable Pure Psyence to produce stable and effective psilocybin medicinal products and work towards making psilocybin more accessible.

  • Dr Amza Ali | Palliative Care | Psyence

The Diaries of a Psychedelic Exec : Episode 8

This week we continue to hear from Dr Amza Ali, neurologist and global medical director at Psyence about palliative care, and Psyence’s vision for making a positive impact on the lives of people suffering from serious illnesses.

  • Dr Amza Ali | Dary of a psychedelic Exec | Psyence

The Diaries of a Psychedelic Exec : Episode 7

Dr Amza Ali is a neurologist and the global medical director at Psyence. In this episode of the Diary of a Psychedelic Exec, Dr Ali shares his thoughts on palliative care, a key focus area for Psyence.

Psyence Group announces the commencement of online sales and distribution of “GOODMIND™” products

We are excited that as of today our functional mushroom nutraceutical product, GOODMIND™ is available online. The GOODMIND™ formulas harness the power of adaptogens, these are non-toxic, non-psychoactive fungi, used for centuries in traditional medicine for their stress-relieving benefits. GOODMIND™ is designed to nourish the mind and elevate everyday life by enhancing mental capacity and the body’s ability to adapt to stress.

  • Diary of a psychedelic exec | episode 06 | Psyence

The Diaries of a Psychedelic Exec : Episode 6

Hi, I am Neil Maresky, the new CEO of Psyence. I am delighted to be able to make a contribution to the “Diary of a Psychedelic Exec”. In this episode I reflect on the challenges society is facing when it comes to mental health and why I think psychedelics, and Psyence in particular, have an important role to play in addressing these challenges. I feel privileged to have the opportunity to lead an incredible team at Psyence, all of whom are clearly committed to making an impact on society.

Why Psyence?

Focused on natural psychedelics

  • Psyence Production: Producing natural psilocybin at our federally licensed facility built to GMP standards
  • Psyence Therapeutics: Proprietary natural psilocybin-based drug research & development as well as treatment protocols for treating psychological trauma and its mental health consequences
  • Psyence Wellness: Uniquely positioned to serve the mental wellness economy valued at $121B market by the Global Wellness Institute
  • Psyence Experience: Innovators in guided-psychedelic experiences

Operational

  • In 2020, Psyence was granted a licence by the Kingdom of Lesotho to cultivate and export psilocybin mushrooms. Our state-of-the-art facility is already operational and is on track for BSI and GMP certification.

Extensive capital markets/business building experience

  • Experienced global executive team
  • Our capital markets team (Bayline Capital Partners) has a track record for creating shareholder value and achieving sustainable growth

International expertise in palliative medicine and science

  • Our scientific and medical team includes Dr. Dingle Spence, a world-renowned expert in the palliative care, Dr. Amza Ali, an internationally recognized neurologist, Tammy Haynes, neuropsychologist, and Dr. Justin Grant, a leader in drug development.
  • Our Scientific Advisory Board is led by Psyence CEO Dr. Neil Maresky, physician and immediate past Vice President of Scientific Affairs at AstraZeneca Canada.

Extensive networks and partnerships

  • We are building partnerships with a network of institutions and companies including:
  • Government research centres
  • University hospitals and research centres
  • Regulatory stakeholders
  • Clinics, retreats and hospitality centres
  • Non-governmental organizations (NGOs)

An IP portfolio in cultivation and therapeutic products

  •  A mix of certified spores under cultivation
  • Psilocybin-based formulations with a focus on the anxiety and mental issues that come with end stage cancer under development
  • Micro-dose products under development to be launched in legal jurisdictions (entered into a JV in Brazil, formulating a truffle version for the Netherlands)

Functional mushroom brand

  • The launch of GOODMIND, the first functional mushroom brand in collaboration with the GoodLeaf Company. Launching our own proprietary Psyence Wellness products in 2021.

Downloads

View Presentation

Financial Statements

Psyence Group SEDAR Profile

Read Here

Psyence Group SEDAR Documents

Read Here

Corporate Details

Transfer Agent

Odyssey

Legal

Weirfoulds LLP

Auditor

MNP LLP

Why Psyence?

Focused on natural psychedelics

  • Psyence Production: Producing natural psilocybin at our federally licensed facility built to GMP standards
  • Psyence Therapeutics: Proprietary natural psilocybin-based drug research & development as well as treatment protocols for treating psychological trauma and its mental health consequences
  • Psyence Wellness: Uniquely positioned to serve the mental wellness economy valued at $121B market by the Global Wellness Institute
  • Psyence Experience: Innovators in guided-psychedelic experiences

Operational

  • In 2020, Psyence was granted a licence by the Kingdom of Lesotho to cultivate and export psilocybin mushrooms. Our state-of-the-art facility is already operational and is on track for BSI and GMP certification.

Extensive capital markets/business building experience

  • Experienced global executive team
  • Our capital markets team (Bayline Capital Partners) has a track record for creating shareholder value and achieving sustainable growth

International expertise in palliative medicine and science

  • Our scientific and medical team includes Dr. Dingle Spence, a world-renowned expert in the palliative care, Dr. Amza Ali, an internationally recognized neurologist, Tammy Haynes, neuropsychologist, and Dr. Justin Grant, a leader in drug development.
  • Our Scientific Advisory Board is led by Psyence CEO Dr. Neil Maresky, physician and immediate past Vice President of Scientific Affairs at AstraZeneca Canada.

Extensive networks and partnerships

  • We are building partnerships with a network of institutions and companies including:
  • Government research centres
  • University hospitals and research centres
  • Regulatory stakeholders
  • Clinics, retreats and hospitality centres
  • Non-governmental organizations (NGOs)

An IP portfolio in cultivation and therapeutic products

  •  A mix of certified spores under cultivation
  • Psilocybin-based formulations with a focus on the anxiety and mental issues that come with end stage cancer under development
  • Micro-dose products under development to be launched in legal jurisdictions (entered into a JV in Brazil, formulating a truffle version for the Netherlands)

Functional mushroom brand

  • The launch of GOODMIND, the first functional mushroom brand in collaboration with the GoodLeaf Company. Launching our own proprietary Psyence Wellness products in 2021.

Investor Sign-Up

Please enter your details below to receive investor updates on Psyence Group


By submitting this form, you are consenting to receive marketing emails from: Psyence Group Inc, 200 Bay Street, Toronto, ON, M5J2J1, https://www.psyence.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Downloads

View Presentation

Financial Statements

Psyence Group SEDAR Profile

Read Here

Psyence Group SEDAR Documents

Read Here

Corporate Details

Transfer Agent

Odyssey

Legal

Weirfoulds LLP

Auditor

MNP LLP
Go to Top